BioSpace News Archive

Biotech Beach

Registration Is Now Open for Tribe Public’s Webinar Event “Revolutionizing Diabetes Care” Featuring Modular Medical CEO on Wednesday, March 6, 2024

Modular Medical will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Revolutionizing Diabetes Care.” The event is scheduled to begin at 8:00am pacific/11:00am eastern on Wednesday, March 6, 2024.

March 4, 2024
·
2 min read
BioForest

Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer’s Disease Clinical Diagnosis

Neurocode USA , Inc is pleased to announce the clinical launch of ALZpath Dx, an innovative and novel blood test that can be used in the screening, diagnosis, and monitoring of Alzheimer’s disease (AD) based on circulating level of pTau217 in the blood.

March 4, 2024
·
4 min read
Deals

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee.

March 4, 2024
·
2 min read
BioCapital

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

March 4, 2024
·
7 min read
Lone Star Bio

Lantern Pharma’s A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024

Lantern Pharma’s A.I. Platform, RADR ® Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines.

March 4, 2024
·
10 min read
Pharm Country

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

UroGen Pharma Ltd. today announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 14, 2024, prior to the open of the stock market.

March 4, 2024
·
1 min read
Genetown

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development.

March 4, 2024
·
4 min read
Business

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024

IPA today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third fiscal year 2024, on Thursday, March 14, 2024, at 10:30 am Eastern Time.

March 4, 2024
·
2 min read
Drug Development

Invitation to Participate in STOP-PC Clinical Trial

Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment.

March 4, 2024
·
6 min read
Drug Development

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Vaxcyte, Inc. today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants.

March 4, 2024
·
10 min read